Mylan Files Annual Report on Form 10-K for Year Ended Dec. 31, 2012
PITTSBURGH, March 4, 2013
PITTSBURGH, March 4, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today
announced that its Annual Report on Form 10-K, containing audited consolidated
financial statements for the year ended Dec. 31, 2012, as filed with the U.S.
Securities and Exchange Commission on Feb. 28, 2013, is available through its
Web site (www.mylan.com). In addition, the company's shareholders may receive
a hard copy of the Annual Report, free of charge, upon request to Investor
Relations at 724.514.1813.
This press release is being issued pursuant to NASDAQ Listing Rule
Mylan is a global pharmaceutical company committed to setting new standards in
health care. Working together around the world to provide 7 billion people
access to high quality medicine, we innovate to satisfy unmet needs; make
reliability and service excellence a habit; do what's right, not what's easy;
and impact the future through passionate global leadership. We offer a growing
portfolio of approximately 1,100 generic pharmaceuticals and several brand
medications. In addition, we offer a wide range of antiretroviral therapies,
upon which approximately 40% of HIV/AIDS patients in developing countries
depend. We also operate one of the largest active pharmaceutical ingredient
manufacturers and currently market products in approximately 140 countries and
territories. Our workforce of more than 20,000 people is dedicated to
improving the customer experience and increasing pharmaceutical access to
consumers around the world. But don't take our word for it. See for yourself.
See inside. mylan.com.
SOURCE Mylan Inc.
Contact: Nina Devlin (Media), +1-724-514-1968, or Kris King (Investors),
Press spacebar to pause and continue. Press esc to stop.